Octaplaslg (Human Plasma Protein)

Octaplaslg is a plasma‑derived protein therapy that addresses disorders of the coagulation cascade and related bleeding complications.

• Major trauma: Provides comprehensive clotting factor replacement to control severe bleeding.
• Cardiac surgery: Assists with hemostasis during and after cardiopulmonary bypass.
• Liver transplantation: Supplies necessary plasma proteins to manage coagulopathy associated with the procedure.

• Octaplaslg contains pooled human plasma proteins, including all essential clotting factors and inhibitors. When infused intravenously, it restores deficient coagulation factors, re‑establishes balanced hemostasis, and helps regulate fibrinolysis, thereby supporting normal clot formation in patients with acquired or procedural bleeding disorders.

Adverse reactions to Octaplaslg are reported across a range of frequencies.

Common Side Effects

• Fever or chills: mild temperature elevation following infusion.
• Headache: transient discomfort often resolving without intervention.
• Nausea: occasional gastrointestinal upset.
• Mild hypotension: slight drop in blood pressure during or shortly after administration.
• Rash or itching: limited skin irritation at the infusion site.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring immediate medical attention.
• Transfusion‑related acute lung injury (TRALI): acute respiratory distress post‑infusion.
• Severe hemolysis: rapid destruction of red blood cells.
• Viral transmission: risk of infection despite rigorous donor screening.
• Thromboembolic events: clot formation in vessels leading to organ compromise.

When using Octaplaslg, clinicians should observe several safety measures.

• Verify patient identity and indication: ensure appropriate clinical need before infusion.
• Monitor vital signs: observe blood pressure, heart rate, and temperature during and after administration.
• Assess for prior transfusion reactions: review patient history for allergies or previous adverse events.
• Use compatible infusion sets: select low‑dead‑space sets to minimize contamination risk.
• Follow aseptic technique: maintain sterility throughout preparation and administration.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the product.

Octaplaslg may interact with other agents that affect coagulation or immune response.

Major Interactions (Avoid)

• High‑dose anticoagulants (e.g., warfarin, heparin): may exacerbate bleeding risk when combined with plasma protein replacement.
• Immunoglobulin products: increased potential for immune complex formation.

Moderate Interactions (Monitor Closely)

• Antifibrinolytics (e.g., tranexamic acid): may augment clot stability, requiring careful coagulation monitoring.
• Platelet inhibitors (e.g., clopidogrel): combined effect on hemostasis should be assessed.
• Cytokine‑modulating therapies: may influence inflammatory response to plasma infusion.